Skip to main content

Table 2 The scores of TTK expression in ovarian cancer patients before and after resistant to cisplatin

From: TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer

 

IHC Scoring

P-value

Negative expression (0)

Weak expression (2–4)

Moderate expression (5–6)

Strong expression (7–8)

When sensitive to cisplatin (n = 20)

0

9

7

4

P < 0.001

After resistant to cisplatin (n = 20)

0

0

3

17